Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | 1.05% | 42.41 | 0.9% | $1154.22m | |
| JNJ | Johnson & Johnson | 1.54% | 136.38 | 0.6% | $1031.22m | |
| MRK | Merck & Co., Inc. | 1.14% | 79.84 | 0.6% | $980.94m | |
| LLY | Eli Lilly and Company | 1.41% | 122.45 | 1.0% | $890.74m | |
| BMY | Bristol-Myers Squibb Company | 1.59% | 51.64 | 1.4% | $801.53m | |
| ABBV | AbbVie, Inc. | 0.40% | 80.84 | 2.2% | $633.73m | |
| AZN | AstraZeneca PLC Sponsored ADR | 2.35% | 40.92 | 1.3% | $202.14m | |
| NVS | Novartis AG Sponsored ADR | 0.98% | 89.89 | 0.2% | $197.85m | |
| GSK | GlaxoSmithKline plc Sponsored ADR | 0.93% | 41.24 | 0.2% | $146.59m | |
| NVO | Novo Nordisk A/S Sponsored ADR Class B | 1.15% | 50.35 | 0.1% | $73.10m | |
| SNY | Sanofi Sponsored ADR | 2.38% | 42.55 | 0.2% | $37.68m | |
| LCI | Lannett Company, Inc. | 4.92% | 9.81 | 37.0% | $16.02m | |
| AKTX | Akari Therapeutics Plc Sponsored ADR | -1.11% | 1.85 | 1.7% | $0.05m | |
| EPIX | ESSA Pharma Inc | 3.88% | 3.75 | 0.1% | $0.05m |
Company Profile
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX). It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP). The company was founded on November 10, 2014 and is headquartered in New York, NY.